Congrats to our outstanding research partners Wednesday, October 02, 2019 This past weekend at the European Society for Medical Oncology congress in Barcelona, Spain, there were many poster presentations by CCTG researchers. Poster Discussion: CCTG IND 232 - Phase II Study of Durvalumab with or without Tremelimumab in Patients with mCRPC The combination of anti-PD-L1 and anti-CTLA-4 is a promising approach because of the non-redundant pathway blockade and synergy based on preclinical data, as well as emerging clinical data. In the phase II CCTGIND 232 trial, the investigators, led by Dr. Sebastien Hotte from Hamilton Health Sciences, tested the hypothesis that dual checkpoint blockade of CTLA-4 with tremelimumab and PD-L1 with durvalumab enhances immune mediated activity in metastatic castration-resistant prostate cancer (mCRPC). Poster Discussion: ENZAMET (CCTG PR17) (NCT02446405) clinical trial - Health Related Quality of Life (HRQoL) Poster Dr. Chris Sweeney and his poster presentation on Overall QoL improved with enzalutamide - Health-related quality of life (HRQoL) in a randomised phase 3 trial of enzalutamide with standard first line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC). Researchers know health-related quality of life is very important to men and their families. So in the ENZAMET trial health-related quality of life of participants was measured. ANZUP evaluated aspects of health-related quality of life such as comfort, happiness, and well-being in men who received enzalutamide, and compared their experience with men receiving standard anti-androgen drug. Poster Discussion: The use of Complementary Medicines is Relatively High Among Patients in CCTG Phase III Cancer Trials Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by the Canadian Cancer Trials Group (CCTG) also used complementary medicines (CMs). The use of CMs was associated with improved survival in patients with lung cancer, although patient baseline characteristics were more favourable in these cohorts. Presented by lead author John C. Wells, Internal Medicine, Queen's University, Kingston. Poster: IND.226 updated data A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients with Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens, aims to confirm the recommended phase II dose (RP2D) of durvalumab ± tremelimumab. Updated results, presented by Dr. Desiree Hao, Medical Oncologist at the Tom Baker Cancer Centre in Calgary, and co-author Dr. Mustapha Tehfe from CHUM.
